NCT04265274 2023-10-06
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
National Cancer Institute, Slovakia
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01020864 2020-11-02
CECAVI
Odense University Hospital
Phase 2 Withdrawn
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn